FDA
-
-
-
-
-
-
-
Veru enrolls first patient in phase 2b trial for weight loss combination
-
-
-
-
-
-
-
Veru Reports Fiscal Year 2025 Financial Results and Clinical Program Progress
-
-
-
-
-
-
-
Veru, Inc. (VERU) PT Lowered to $20 at Raymond James
-
-
-
-
-
-
-
Veru Announces Reverse Stock Split
-
-
-
-
-
-
-
Veru Reports Positive Safety Results from Phase 2b QUALITY Study: Enobosarm Added to Semaglutide Led to Greater Fat Loss, Preservation of Muscle, and Fewer Gastrointestinal Side Effects Compared to Se
-
-
-
-
-
-
-
Veru to Report Fiscal 2025 First Quarter Financial Results on February 13, 2025
-
-
-
-
-
-
-
Veru to Present at the 17th International Conference of the Society on Sarcopenia, Cachexia, & Wasting Disorders
-
326,558 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

